Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Capecitabine in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
NCT05044117Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2021
- Primary completion
- Oct 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen University. Started Oct 2021; status: recruiting.
02
Drugs
capecitabine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05044117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044117.